朗读者

China approves first-ever drug for acute mountain sickness prevention_我的网站

一 |     

    Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness. 
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source. 
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations. 
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。    　　好评中国·“经”彩开局｜加大逆周期调节力度 推动经济持续向好　　当前我国经济呈现出动能向新、结构向优的发展态势，但“供强需弱”的矛盾依然较为突出。近期召开的中共中央政治局会议在部署下半年经济工作时强调，“加大逆周期调节力度”。

二 | 　　所谓逆周期调节，是指政府根据经济周期阶段，通过政策工具和措施让整个经济周期的波动性平缓，更好促进经济发展。通俗讲，就是在经济过热时适度“踩刹车”，在经济下行遇冷时果断“加油门”。这种调节是对市场机制的必要补充。市场自身存在顺周期特性，繁荣时易过度乐观、投资膨胀，衰退时过度悲观、需求萎缩，这种自我强化的循环往往加剧经济波动。而逆周期调节通过提前释放政策信号，能够进一步引导经营主体强信心、稳定社会预期。　　当前，经济运行中出现了一些新变化、新动向，但也面临一些困难和挑战。从供求关系看，消费新增长点不断涌现，但商品消费恢复偏缓，投资内生动力不足；从经济结构看，新产业、新业态、新模式较快成长，但部分传统产业和中小企业经营面临困难，不同行业、不同区域在新旧动能转换中发展出现分化。此时加大逆周期调节力度，能够有效对冲经济下行压力、扩大有效内需、稳定市场信心。　　逆周期调节涉及财政、货币、产业等多领域，若步调不一致，极易产生“合成谬误”。

三 | 因此，必须坚持系统思维，强化政策协同，在“适时调整”中把握好力度与节奏。今年以来，财政金融协同促内需一揽子政策加快落地，效果逐步显现。接下来，需要实施好更加积极的财政政策和适度宽松的货币政策，加快财政支出和债券资金使用进度，推动尽快形成实物工作量。　　从货币政策看，总量工具与结构性工具的搭配使用，是逆周期调节的鲜明特色。总量工具保障流动性合理充裕，为市场提供稳定的利率预期；结构性工具则要精准滴灌，定向支持扩大内需、科技创新和中小微企业等重点领域。7月，新发放企业贷款加权平均利率略低于3%，融资成本实实在在降下来了，更多中长期资金加速流向制造业、中小微企业和科技创新领域。　　从财政政策看，则要在“积极”上做足文章。一方面，推动各项既定政策落地实施，合理加快资金使用进度，持续支持扩大有效投资，挖掘消费潜力，强化民生保障，促进基层财政平稳运行。今年前7个月，设备工器具购置投资同比增长9.0%，不少制造业企业借此契机完成了产线的“焕新升级”。另一方面，根据宏观经济运行情况，及时谋划出台务实管用的增量政策，为实现经济质的有效提升和量的合理增长提供有力支撑。　　长远来看，解决我国稳增长和提质增效的问题，需要加强逆周期调节与跨周期调节政策的密切配合，引导资源精准流向实体经济、科技创新、绿色低碳发展等重点领域。盘活存量政策、用好增量工具，强化协同联动、狠抓落地见效，持续提升宏观调控效能，必将有力推动我国经济持续向新向优向好发展。(中国经济网专栏作者 乔瑞庆)　　来源：中国经济网。

Current article:http://62byx9i.cuiguagonggengaotianwan.shop/list_xrllol/e0s71gc.html

Published on:04:44:11